Back to top
more

The Cooper Companies (COO)

(Delayed Data from NSDQ)

$71.45 USD

71.45
1,416,982

+0.58 (0.82%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $71.44 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.

Zacks Equity Research

OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

Zacks Equity Research

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.

Zacks Equity Research

Stryker (SYK) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.

Zacks Equity Research

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.

Zacks Equity Research

Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?

by Zacks Equity Research

Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.

Zacks Equity Research

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.

Zacks Equity Research

Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.

Zacks Equity Research

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.

Zacks Equity Research

Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?

by Zacks Equity Research

Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.

Zacks Equity Research

New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings

by Zacks Equity Research

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.

Zacks Equity Research

Hologic (HOLX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Hologic (HOLX) is likely to have gained during fiscal second-quarter 2021 on the back of robust performances of its business arms despite coronavirus-led economic doldrums.

Zacks Equity Research

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.

Zacks Equity Research

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

Zacks Equity Research

Why You Should Hold AngioDynamics (ANGO) in Your Portfolio

by Zacks Equity Research

Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.

Zacks Equity Research

Cardinal Health (CAH), HHS Partner to Offer Pandemic Support

by Zacks Equity Research

The contract should help Cardinal Health (CAH) provide critical pandemic support in partnership with the U.S. government.

Zacks Equity Research

Here's Why You Should Hold on to LabCorp (LH) Stock Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.

Zacks Equity Research

Here's Why You Should Hold Masimo (MASI) in Your Portfolio

by Zacks Equity Research

Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

by Zacks Equity Research

Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.

Zacks Equity Research

Here's Why You Should Retain Quest Diagnostics (DGX) Stock

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.

Zacks Equity Research

What Makes The Cooper Companies (COO) a New Buy Stock

by Zacks Equity Research

The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Why Cooper Companies (COO) Stock Might be a Great Pick

by Zacks Equity Research

Cooper Companies (COO) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Now

by Zacks Equity Research

Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Dental Supplies Industry

by Trina Mukherjee

Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.

Zacks Equity Research

Here's Why You Should Buy Align Technology (ALGN) Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on robust international performance and continued portfolio expansion.